Analysis
Latigo Biotherapeutics priced an upsized initial public offering at $18.00 a share -- the top of its marketed $16-$18 range -- selling 19.2 million shares to raise $345.6 million, and closed its first trading day up 17% after opening at $21, according to Bloomberg. The offering gives the Thousand Oaks, California-based company a market value of roughly $1.3 billion under the ticker LTGO on the Nasdaq Global Select Market.
What changed since Latigo first filed: the company had set terms for a $272 million raise at the same $16-$18 range just days earlier, according to Renaissance Capital; by pricing day, demand pushed the deal 27% larger and priced it at the top of the range rather than the middle. Blue Owl Capital-backed Latigo develops non-opioid pain medicines targeting the Nav1.8 sodium channel -- the same target class Vertex has staked its own pain franchise on -- and its lead candidate, LTG-001, recently reported positive Phase 2 data from a 343-patient abdominoplasty trial, meeting its primary endpoint against placebo. Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities served as bookrunners.
“Goldman Sachs, Jefferies, Leerink Partners and Guggenheim Securities served as bookrunners.”
Pulse tracked the broader reopening of the biotech IPO window earlier this week, when BlossomHill and Braveheart Bio both priced above their original targets. Latigo is now the third biotech name in roughly ten days to clear an upsized, above-range deal -- a pattern that, unlike BlossomHill and Braveheart, comes with real human efficacy data already in hand rather than a story investors have to take on faith.
That distinction matters for how durable the reopening actually is. A pre-data biotech pricing well is a bet on sentiment; Latigo pricing well on top of positive Phase 2 results is closer to a bet on the science itself, which is a sturdier signal if the window tightens again. The risk sitting underneath the pop: LTG-001 still needs to clear two Phase 3 trials -- a placebo-controlled bunionectomy study and an open-label safety trial -- before it's a commercial product, and first-day pops on biotech IPOs have reversed hard before once lockup-adjacent selling begins.
